AI assistant
BIOGEN INC. — Director's Dealing 2019
Sep 26, 2019
30291_dirs_2019-09-26_843e84fb-3e6b-48f5-9ad0-2ff55a37f86a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2019-09-19
Reporting Person: Galdes Alphonse (EVP Pharmaceutical Oper & Tech)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1428.264 | Direct |
| Common Stock | 969.366 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Restricted Stock Unit | $0 | 2020-02-12 | Common Stock (484) | Direct | |
| Restricted Stock Unit | $0 | 2022-02-12 | Common Stock (2340) | Direct | |
| Restricted Stock Unit | $0 | 2021-02-12 | Common Stock (1214) | Direct | |
| Restricted Stock Unit | $0 | 2020-02-15 | Common Stock (774) | Direct |
Footnotes
F1: This award was granted to the reporting person on February 12, 2018. The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.
F2: This award was granted to the reporting person on February 12, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F3: This award was granted to the reporting person on February 12, 2018. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F4: This award was granted to the reporting person on February 15, 2017. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).